An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions

Histopathology

Volumn 63, Issue 2, 2013, Pages 250-262

  Bahrami, Armita ^a   Perez Ordonez, Bayardo ^b,c   Dalton, James D ^a   Weinreb, Ilan ^b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ductal carcinoma in situ; HMGA2; Low grade cribriform cystadenocarcinoma; PLAG1; Pleomorphic adenoma; Precursor; Salivary duct carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH MOBILITY GROUP A2 PROTEIN; PLAG1 PROTEIN; PROTEIN; PROTEIN P63; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MYOEPITHELIUM; NECK DISSECTION; PRECURSOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; STAINING;

EID: 84880729118     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12152     Document Type: Article

References (23)

1. Barnes L, Eveson JW, Reichart P et al. eds. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005.
2. Skálová A, Stárek I, Vanecek T et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003; 42; 348-356.
3. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin. Cancer Res. 2010; 16; 2266-2274.
4. Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R. Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum. Pathol. 2010; 41; 927-934.
5. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum. Pathol. 2001; 32; 596-604.
6. Nakatsuka S, Harada H, Fujiyama H et al. An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma? Diagn. Pathol. 2011; 6; 122.
7. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordoñez B. Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am. J. Surg. Pathol. 2006; 30; 1014-1021.
8. Delgado R, Klimstra D, Albores-Saavedra J. Low grade salivary duct carcinoma. A distinctive variant with a low grade histology and a predominant intraductal growth pattern. Cancer 1996; 78; 958-967.
9. Brandwein-Gensler M, Hille J, Wang BY et al. Low-grade salivary duct carcinoma: description of 16 cases. Am. J. Surg. Pathol. 2004; 28; 1040-1044.
10. Laco J, Podhola M, Dolezalova H. Low-grade cribriform cystadenocarcinoma of the parotid gland: a neoplasm with favorable prognosis, distinct from salivary duct carcinoma. Int. J. Surg. Pathol. 2010; 18; 369-373.
11. de Araújo VC, Kowalski LP, Soares F, de Araújo NS, Loducca SV, Sobral AP. Salivary duct carcinoma: cytokeratin 14 as a marker of in-situ intraductal growth. Histopathology 2002; 41; 244-249.
12. Di Palma S, Simpson RH, Marchiò C et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 2012; 61; 629-643.
13. Bahrami A, Dalton JD, Shivakumar B, Krane JF. PLAG1 alteration in carcinoma ex pleomorphic adenoma: immunohistochemical and fluorescence in situ hybridization studies of 22 cases. Head Neck Pathol. 2012; 6; 328-335.
14. Martins C, Fonseca I, Roque L et al. PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma: a combined study using chromosome banding, in situ hybridization and immunocytochemistry. Mod. Pathol. 2005; 18; 1048-1055.
15. Bahrami A, Dalton JD, Bangalore S et al. Disseminated carcinoma ex pleomorphic adenoma in an adolescent confirmed by application of PLAG1 immunohistochemistry and FISH for PLAG1 rearrangement. Head Neck Pathol. 2012; 6; 377-383.
16. Bahrami A, Dalton JD, Krane JF, Fletcher CD. A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosom. Cancer 2012; 51; 140-148.
17. Gnepp DR, Wang LJ, Brandwein-Gensler M, Slootweg P, Gill M, Hille J. Sclerosing polycystic adenosis of the salivary gland: a report of 16 cases. Am. J. Surg. Pathol. 2006; 30; 154-164.
18. Fahim L, Weinreb I, Alexander C, Perez Ordoñez B. Epithelial proliferation in small ducts of salivary cystadenoma resembling atypical ductal hyperplasia of breast. Head Neck Pathol. 2008; 2; 213-217.
19. Fulciniti F, Losito NS, Ionna F et al. Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn. Cytopathol. 2010; 38; 368-373.
20. Ihrler S, Weiler C, Hirschmann A et al. Intraductal carcinoma is the precursor of carcinoma ex pleomorphic adenoma and is often associated with dysfunctional p53. Histopathology 2007; 51; 362-371.
21. Weiler C, Zengel P, van der Wal JE et al. Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 2011; 59; 741-750.
22. Gnepp DR. Sclerosing polycystic adenosis of the salivary gland: a lesion that may be associated with dysplasia and carcinoma in situ. Adv. Anat. Pathol. 2003; 10; 218-222.
23. Simpson RH, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology 2008; 53; 416-425.